BioDelivery Sciences (BDSI) Reports Q3 EPS of $0.10

BioDelivery Sciences (NASDAQ: BDSI) reported Q3 EPS of $0.10, versus ($0.01) reported last year. Revenue for the quarter came in at $42.2 million, versus $31.6 million reported last year.

Financial Guidance:

The Company expects full year 2021 total net sales of $170 - $180 million, including full year 2021 BELBUCA net sales of $155 - $165 million. These estimates incorporate the expected impact in Q1 2021 from the winter storms in the South-Central region, which affected some of the Company’s most productive territories. Total operating expenses are expected to be in the range of $115 - $120 million, as the Company continues to invest to support the growth of its brands, and EBITDA is expected to be in the range of $40 - $50 million in 2021. The Company expects to continue being operating cash flow positive throughout 2021.

“I’m proud of how the BDSI team really pulled together, and also thrived, during 2020 in what was a challenging year for the industry due to the pandemic. I would like to recognize the efforts and contributions of all BDSI employees. I have great confidence that, with the strength of this team, high-growth brands, and a strong balance sheet, BDSI will continue to drive long-term shareholder value,” stated Jeff Bailey.

For earnings history and earnings-related data on BioDelivery Sciences (BDSI) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Is Treasury selloff a major issue for stock market bulls?
• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown